BENGALURU (Reuters) – Aurobindo Pharma Ltd on Thursday said it would sell US-based Kovacs’ Covit-19 vaccine candidate to the United Nations Children’s Fund (UNICEF) under a license agreement to supply and sell it in India.
The Indian-based pharmaceutical manufacturer has exclusive rights to sell the shot – which is currently under early testing – in a few other emerging markets, the Hyderabad-based company said in an exchange filing.
Kovacs, a division of privately owned United Biomedical Inc., plans to continue mid- and post-testing of the vaccine candidate in Asia, Latin America and the United States from early 2021.
In contrast to the freezing temperatures required for some vaccines, Shot uses normal refrigeration, which is considered beneficial for developing countries.
Shares of Aravindo Pharma rose 2.3% and traded up 1.4% at 0403 GMT in the Mumbai market.
Aurobindo said it could currently produce 220 million units, but is increasing its facilities to reach a capacity of nearly 480 million by June 2021.
COVID-19 has come under its license agreement as the number of COVID-19 infections continues to rise in India after it crossed 10 million last week. It is the second most infected country after the United States.
Reuters reported on Tuesday that the country is likely to approve the Oxford / Astrogeneka corona virus vaccine for emergency use within the next week.
India, the world’s largest vaccine manufacturer, is also considering emergency application for horoscopes for vaccines manufactured by Pfizer and local company Bharat Biotech.
Last month, COVAXX announced that it had received a total of $ 2.8 billion in purchase loans to supply more than 140 million of its potential COVID-19 vaccine to developing countries, including Brazil, Peru and Ecuador.
(Report by Anuran Kumar Mitra in Bangalore; Compiled by Rashmi)